-
Obeticholic Acid FXR Workflows for Liver Research
2026-09-15
Build receptor-proximal assays with Obeticholic Acid to connect FXR activation with bile acid transport, cholestasis, and fibrosis-relevant phenotypes. The workflow also shows how to compare FXR readouts with the Notch and natural-killer-cell findings from a recent liver fibrosis study without conflating distinct mechanisms.
-
LNP-miR-200c Suppresses Pancreatic Cancer Progression
2026-09-15
Yu et al. show that miR-200c functions through two separable regulatory routes in pancreatic cancer: nuclear activation of PTPN6 through an enhancer and post-transcriptional repression of CDH17. LNP-mediated delivery reproduced the antitumor effect in vivo, providing a mechanistic rationale for studying miRNA localization, enhancer regulation, and delivery together.
-
Recombinant Mouse M-CSF for Causal Assays
2026-09-14
Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) is more than a differentiation reagent: it is a critical variable in macrophage assay design. This article connects PM2021 specifications with the IGF2BP1–THBS1–TLR4 fibrosis mechanism to improve causal interpretation, controls, and workflow selection.
-
SPI1–Wnt5a Signaling in Intracranial Aneurysm
2026-09-14
A 2026 study identifies SPI1 as a transcriptional regulator that promotes intracranial aneurysm formation by suppressing Wnt5a and activating canonical Wnt/β-catenin signaling. Its combined cell, chromatin, and mouse-model evidence links this axis to vascular smooth muscle cell phenotypic switching, arterial wall injury, and inflammation.
-
Necrosome Assembly and RIP3 Stoichiometry
2026-09-13
This study combines quantitative STORM imaging with mathematical modeling to identify an approximately 3:1 RIP3:RIP1 stoichiometry that optimizes necrosome-driven necroptosis. It also shows that excessive RIP3 oligomerization attenuates signaling, revealing how signalosome size and composition jointly balance amplification with response control.
-
Catalpol in Cardio-Cerebrovascular Disease Research
2026-09-12
This comprehensive review maps catalpol’s antioxidant, anti-inflammatory, and anti-apoptotic activities across major cardio-cerebrovascular disease settings and links them to pathways including PI3K/Akt, AMPK, Nrf2/HO-1, and PGC-1α/TERT. Its main practical value is an integrated framework connecting compound chemistry, pharmacokinetics, disease models, and translational limitations rather than a single therapeutic claim.
-
EGTA for Calcium Signaling and Neuroprotection
2026-09-12
EGTA, or egtazic acid, gives researchers a controllable way to lower extracellular free calcium while separating calcium-dependent signaling from receptor or channel activation. This guide translates cardiac vagal neuron electrophysiology into practical workflows for neuroprotection, calcium imaging, viability testing, and apoptosis assays, with emphasis on solubility, controls, and interpretation.
-
Bsa I (RNase-free): Practical DNA Cleavage Guide
2026-09-11
Bsa I (RNase-free), SKU K1095, provides sequence-directed type IIS DNA cleavage for gene cloning, DNA manipulation, and related molecular biology research workflows where RNA degradation should be minimized. It is intended for controlled scientific research only, not diagnostic, clinical, or medical use, and reaction conditions must be confirmed against the current product instructions.
-
Pyridostigmine, α-Bungarotoxin, and Placental Necroptosis
2026-09-11
The reference study identifies placental necroptosis as a modifiable component of preeclampsia-like pathology and shows that pyridostigmine improves several disease-associated outcomes in the RUPP rat model. Pharmacological blockade with α-bungarotoxin implicates α7 nicotinic acetylcholine receptor signaling in these effects, while hypoxic trophoblast experiments extend the mechanism to inflammation and cell migration.
-
CLCC1 and Herpesvirus Nuclear Egress
2026-09-10
A whole-genome CRISPR screen identified the host protein CLCC1 as essential for the membrane-fusion stage of herpesvirus nuclear egress. The findings connect herpesvirus capsid export with nuclear pore insertion and suggest an evolutionarily conserved cellular membrane-remodeling mechanism, while leaving the direct molecular role of CLCC1 unresolved.
-
Telmisartan: A Causal Benchmark for Cardiac Hypertrophy
2026-09-10
Telmisartan is an angiotensin II receptor antagonist that can serve as a receptor-proximal benchmark in cardiac hypertrophy experiments. This article contrasts AT1R blockade with RIP3/CaMKII biology and shows how to design assays that distinguish initiating signals from downstream remodeling.
-
Cabazitaxel Workflow for Resistant Cancer Models
2026-09-09
Cabazitaxel (XRP6258, SKU B2157) provides a practical taxane-based option for evaluating antiproliferative responses in P-glycoprotein-expressing and taxane-resistant cancer models. It is suited to controlled DMSO- or ethanol-based workflows, but is insoluble in water, and prepared solutions should be used promptly rather than stored long term.
-
ALDH2 Activation Delays Pressure-Overload Heart Failure
2026-09-08
A 2025 Experimental Cell Research study identifies ALDH2 activation as a way to extend the postnatal proliferative window of mouse cardiomyocytes and delay pressure-overload heart failure. The work positions Alda 1-based ALDH2 activation as a research strategy linking aldehyde detoxification, cardiomyocyte cell-cycle control, and cardiac remodeling, while leaving human translation and long-term regeneration unresolved.
-
Fosinopril Clinical Pharmacokinetics and Potential
2026-09-08
The 1997 review by Shionoiri and colleagues defined fosinopril’s clinical significance through its prodrug conversion, phosphinic acid-mediated ACE inhibition, and combined biliary and renal elimination of fosinoprilat. Its findings remain useful for interpreting blood pressure reduction, renal function, dialysis, hemodynamic effects, and drug-interaction evidence in hypertension research.
-
Dabigatran Etexilate: Oral Thrombin Inhibition
2026-09-07
The 2011 review by Blommel and Blommel presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States and explains how prodrug design addressed important limitations of warfarin and injectable anticoagulants. Its synthesis of pharmacology, pharmacokinetics, clinical efficacy, safety, and renal handling remains useful for interpreting thrombin inhibition mechanism studies and anticoagulant research.